A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (MEMENTO)
MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain NCT # and Site #.
Study Locations
-
-
-
Buenos Aires, Argentina, 1199
- Local Institution - 0080
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 1093
- Local Institution - 0076
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1428ART
- Local Institution - 0075
-
Pilar, Buenos Aires, Argentina, B1629ODT
- Local Institution - 0079
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, X5021FPQ
- Local Institution - 0077
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000GAP
- Local Institution - 0074
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Local Institution - 0015
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- Local Institution - 0085
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Local Institution - 0005
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Local Institution - 0001
-
Québec, Quebec, Canada, G1V 4G5
- Local Institution - 0068
-
-
-
-
-
Geneva, Switzerland, 1205
- Local Institution - 0061
-
Zürich (de), Switzerland, 8091
- Local Institution - 0024
-
-
Luzern (de)
-
Lucerne, Luzern (de), Switzerland, 6000
- Local Institution - 0058
-
-
Ticino (it)
-
Lugano, Ticino (it), Switzerland, 6900
- Local Institution - 0029
-
-
-
-
Yorkshire
-
Leeds, Yorkshire, United Kingdom, LS1 3EX
- Local Institution - 0025
-
-
-
-
California
-
West Hollywood, California, United States, 90048-1804
- Local Institution - 0087
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Local Institution - 0003
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Local Institution - 0093
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Local Institution - 0090
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212-4756
- Local Institution - 0086
-
-
Texas
-
Houston, Texas, United States, 77030
- Local Institution - 0017
-
-
Utah
-
Murray, Utah, United States, 84107-5701
- Local Institution - 0035
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:.
- Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mmHg and ≥ 50 mmHg after Valsalva or after exercise.
- Left ventricular ejection fraction (LVEF) ≥ 55% at rest.
- New York Heart Association (NYHA) functional class II or III symptoms.
Exclusion Criteria
- A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM.
- Documented obstructive coronary artery disease or history of myocardial infarction.
- A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening.
- An implantable cardioverter defibrillator (ICD) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (CMR).
- Other protocol-defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mavacamten
|
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48
Time Frame: At week 48
|
Participants achieving both of the following criteria at Week 48 cardiac magnetic resonance imaging (CMR) assessment:
|
At week 48
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants who had at least 1 class of improvement from baseline in New York Heart Association (NYHA) class at Week 48
Time Frame: At week 48
|
At week 48
|
|
Change from baseline in left ventricular mass index (LVMI) at Week 48
Time Frame: At week 48
|
At week 48
|
|
Incidence of major adverse cardiac events (MACE)
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of MACE-expanded events
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
All-cause mortality
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of heart failure (HF) events
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of atrial fibrillation (AF)/atrial flutter
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of ventricular tachyarrhythmias
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of nonvasovagal syncope and seizures
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of treatment emergent adverse events (TEAEs)
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Severity of TEAEs
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of treatment emergent serious adverse events (SAEs)
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Change from baseline in maximum left atrial volume index (LAVI) at Week 48
Time Frame: At week 48
|
At week 48
|
|
Incidence of HF events with systolic dysfunction
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Incidence of cardiovascular (CV) mortality
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
TEAEs leading to discontinuation from study intervention
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
TEAEs leading to laboratory abnormalities
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CV027-1088
- 2022-502316-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.